Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Or leave a message with a formal purchase order (PO) Or credit card.
SARS-CoV-2 Spike RBD Monoclonal Antibody
PA007140: SARS-CoV-2 Spike RBD Monoclonal Antibody
Human IgG Monoclonal Antibody.
The monoclonal SARS-CoV-2 (2019-nCoV) spike antibody (S protein antibody, spike S1 antibody) was produced in mammalian cells.
Specificity/Sensitivity: The monoclonal SARS-CoV-2 (2019-nCoV) spike RBD antibody binds to SARS-CoV-2 and SARS-CoV spike RBD, S protein, and S1 subunit.
Applications: ELISA 1:10000, Flow Cytometry 1:500. It might be used as the human IgG antibody positive control for serological assays to detect SARS-CoV and SARS-CoV-2 infection.
Form of Antibody: 1 mg/ml in PBS, pH 7.4.
Isotype: hIgG1, H+L.
Purity: >95% by SDS-PAGE under reducing conditions.
Shipping: The monoclonal SARS-CoV-2 spike RBD antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Please ask for a quote if you need the recombinant spike RBD monoclonal antibody as the human IgM antibody positive control for serological assays. To check more Syd Labs SARS-CoV-2 (2019-nCoV) Antigen and Antibody Reagents and Discovery Services
The receptor binding domain (RBD) in the S1 subunit of the SARS-CoV-2 (2019-nCoV) spike (S) glycoprotein plays the most important roles in viral attachment, fusion and entry. The SARS-CoV and SARS-CoV-2 S proteins mediate viral entry into host cells by binding to a host receptor, angiotensin-converting enzyme 2 (ACE2), through the receptor-binding domain (RBD) in the S1 subunit, and then fusing the viral and host membranes through the S2 subunit. The ACE2-binding affinity of the Spike RBD of SARS-CoV-2 is 10- to 20-fold higher than that of SARS-CoV.
The SARS-CoV-2 S protein, especially its S1 subunit and RBD, has become a popular target of antibodies for diagnostics test, and proteins and antibodies for therapeutic drugs. The amino-acid sequence identity is around 74% between the RBDs in the SARS-CoV and SARS-CoV-2 S proteins, similar to the 77% identity between the whole S proteins of SARS-CoV and SARS-CoV-2. Such a high degree of sequence similarity raises the possibility that cross-reactive epitopes may exist. Although the SARS-CoV RBD polyclonal antibodies can recognize both viruses, only one out of a few published RBD monoclonal antibodies neutralizing SARS-CoV binds to SARS-CoV-2 spike RBD. Out of the 28 residues in the epitope of the S1 RBD monoclonal antibody, only 4 residues (14%) in SARS-CoV-2 S1 RBD are different from those in SARS-CoV S1 RBD. However, the S1 RBD mAb binds to SARS-CoV spike RBD (Kd = 1 nM) with a much higher affinity than to SARS-CoV-2 spike RBD (Kd = 115 nM, or 6.3 nM measured by another lab). It remains unreported that the S1 RBD neutralizing monoclonal antibody from a recovered SARS patient also behaves as a neutralizing antibody of SARS-CoV-2.
Syd Labs also provide custom antibody discovery services to screen more and better antibodies for therapeutic drugs, diagnostic immunoassays, and research reagents:
SARS-CoV-2-specific human neutralizing monoclonal antibody development service: If a client or collaborator provides PBMC from recovered COVID-19 patients or people with SARS-CoV-2 vaccines, Syd Labs can do single B cell sorting and culturing. We can send out about 70 ul supernatant per well (clonal single B cell) for quick screening. Then you tell us which single B cell clone you like. We sequence the antibody VH/VL and produce the recombinant human monoclonal antibody for your confirmation. The efficiency is much higher than antibody cloning and sequencing immediately after single B cell sorting; of course, the total cost is much lower. A few groups have used the single B cell method without culturing after sorting to identify some neutralizing monoclonal antibodies against the SARS-CoV-2 spike protein, especially its S1 RBD. It remains unknown how good they are to become therapeutic drugs. Using the strategy without culturing, one may screen antibodies from hundreds of single B cells after a lot of efforts; however, one may easily screen antibodies from thousands of single B cells.
SARS-CoV-2 Spike S1 rabbit monoclonal antibody development service: Syd Labs immunized rabbits with SARS-CoV-2 S protein S1 subunit, then did single B cell sorting and culturing. S1 subunit may be better than its RBD as the immunogen. There will be about 70 ul supernatant per well (clonal single B cell). If a client is interested in rabbit monoclonal antibodies against SARS-CoV-2 Spike protein (S protein), we can send you some supernatant for quick screening. Then you tell us which single B cell clone you like. We sequence the antibody VH/VL and produce a recombinant rabbit monoclonal antibody for your confirmation. You can pay for the antibody or the clone.
SARS-CoV-2 Nucleocapsid rabbit monoclonal antibody development service: Syd Labs immunized rabbits with SARS-CoV-2 Nucleocapsid protein (N protein), then did single B cell sorting and culturing. All the process is the same as "SARS-CoV-2 Spike S1 rabbit monoclonal antibody development service".
SARS-CoV-2 spike S1 and Nucleocapsid VHH nanobody development service: Syd Labs will immunize alpaca with SARS-CoV-2 S protein S1 subunit and Nucleocapsid protein, then do single B cell sorting and culturing or construct VHH nanobody phage display libraries. All the process is the same as "SARS-CoV-2 Spike S1 rabbit monoclonal antibody development service". The spike nanobodies may be good candidates for therapeutic drugs alone or by combination with other proteins or antibodies; the nucleocapsid nanobodies may be used for diagnostic test kits.
To know more about our human, rabbit, and alpaca (camelid) monoclonal antibody development services, please visit: